Bioinformatics analysis to determine the prognostic value and prospective pathway signaling of miR-126 in non-small cell lung cancer
Original Article

Bioinformatics analysis to determine the prognostic value and prospective pathway signaling of miR-126 in non-small cell lung cancer

Zichen Jiao1,2#, Ao Yu1,2#, Xiaofeng He1,2#, Yulong Xuan1,2, He Zhang1, Guojun Wang3, Minke Shi1,2, Tao Wang1,2

1Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China; 2Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Nanjing Medical University, Nanjing, China; 3Department of Thoracic Surgery, Jintan People’s Hospital, Changzhou, China

Contributions: (I) Conception and design: Z Jiao, A Yu, T Wang; (II) Administrative support: Z Jiao, T Wang; (III) Provision of study materials or patients: Z Jiao, A Yu, T Wang; (IV) Collection and assembly of data: Z Jiao, X He, Y Xuan, H Zhang, G Wang; (V) Data analysis and interpretation: Z Jiao, Y Xuan, H Zhang, G Wang, M Shi; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Tao Wang. Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. Email:; Minke Shi. Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. Email:; Guojun Wang. Department of Thoracic Surgery, Jintan People’s Hospital, Changzhou, China. Email:

Background: MicroRNAs (miRNAs) have been demonstrated to play crucial roles in the initiation and development of non-small cell lung cancer (NSCLC). However, further investigation of the specific role of miR-126 in NSCLC is still required.

Methods: An analysis of miR-126 expression in NSCLC was carried out using the Gene Expression Omnibus (GEO) database, and a literature review was also performed. The differentially expressed genes (DEGs) in three mRNA datasets, GSE18842, GSE19804, and GSE101929, from GEO were identified. Following the prediction of hsa-miR-126-5p target genes by TargetScan, the overlap of miR-126 target genes with DEGs in NSCLC was examined. After that, Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed. Finally, an analysis to identify the impact of hub genes on the prognosis of NSCLC was carried out on the basis of a protein-protein interaction (PPI) network constructed using STRING and Cytoscape.

Results: The data in the literature review revealed a trend that miR126 was downregulated in NSCLC. The number of both NSCLC-related and miR-126-related DEGs was 187. Dozens of DEGs were significantly enriched in biological regulation, cell membrane binding, and signal receptor binding. In the PPI network analysis, 3 of 10 identified hub genes, namely NCAPG, MELK, and KIAA0101, were obviously related to poor prognosis in NSCLC; the survival rate was low among patients with high expression levels of these genes. Furthermore, through network analysis, TPX2, HMMR, and ANLN were identified as recessive miR-126-related genes that may be involved in NSCLC.

Conclusions: MiR-126 plays an essential role in the biological processes of NSCLC through binding to target genes and influences the prognosis of patients with the disease.

Keywords: Non-small cell lung cancer (NSCLC); miR-126; differentially expressed genes (DEGs); functional factors

Submitted Sep 04, 2020. Accepted for publication Dec 16, 2020.

doi: 10.21037/atm-20-7520


Lung cancer ranks first among all cancers in terms of global incidence and mortality. Due to its high degree of malignancy, effective treatments for lung cancer are currently lacking (1). In China, the numbers of new cases and deaths associated with lung cancer have gradually increased in recent years (2). The pathogenesis of lung cancer is unclear and its early symptoms vary from patient to patient. As a consequence, a majority of patients are already at the middle or late stages of the disease by the time of histopathological diagnosis, meaning their best opportunity for early surgical intervention is missed. However, even in patients who are able to undergo surgery to achieve complete tumor resection, the rates of recurrence and metastasis during follow-up are often as high as 1/3 (3).

A majority of cases of lung cancer are non-small cell lung cancer (NSCLC). In-depth study and investigation of driver genes in lung cancer have led to an improved understanding of the molecular biology of NSCLC, and therapies targeting driver genes have achieved remarkable results. Targeted therapy, a new therapeutic approach for lung cancer, has achieved an improvement in efficiency and safety, and also has low toxicity, high accuracy, and minimal adverse effects (4,5). In particular, advancements in next-generation sequencing (NGS) technology have led to the promotion of driver gene detection in NSCLC and the subsequent development of targeted therapy (6).

Therefore, the identification of new targets related to the prognosis of NSCLC and further elucidation of the underlying mechanisms would significantly improve the clinical effect of targeted therapy as well as the quality of life for patients with NSCLC.

MicroRNAs (miRNAs), as non-coding small-molecule RNAs, are completely or partially complementary to the three prime untranslated region (3'-UTR), coding sequence (CDS), or promoter region of messenger RNAs (mRNAs). Post-transcriptionally, miRNAs regulate gene expression by inhibiting mRNA translation or directly degrading target mRNA (7). Studies on miRNAs and their various regulatory functions have shown them to play multiple roles in physiological and pathological processes, such as cell differentiation, proliferation, and apoptosis; moreover, their importance in the initiation and development of various tumors has also been reported (8,9). Abnormal expression of miR-126-5p (miR-126) has increasingly been proved to participate in biological processes of multiple cancers. Wei et al. reported that miR-126 inhibited the viability of colorectal cancer cells by hindering apoptosis and autophagy induced by mammalian target of rapamycin (mTOR) (10). In malignant mesothelioma, miRNAs can, through the regulation of epigenetics, serve as biomarkers for early diagnosis and treatment (11). In their study, Kim et al. (12) concluded that the production of mouse embryonic stem cell-derived FLK1+ cells was regulated by the ETV2/ER71 via miR-126-MAPK pathway. In some studies on the mechanism of miR-126 in the regulation of the malignant biological behavior of NSCLC cells, the results showed that miR-126 could regulate susceptibility to apoptosis, migration, cycle, and proliferation via the STAT3 signaling pathway (13). Moreover, previous studies have confirmed that the expression level of miR-126 is consistently down-regulated in NSCLC and plays a pivotal role in prognosis (14,15).

Therefore, this study aimed to explain the role of miR-126 in NSCLC and to confirm its potential molecular targets through a bioinformatics analysis using Gene Expression Omnibus (GEO) datasets, and a literature review.

We present the following article in accordance with the MDAR reporting checklist (available at


The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Selection of GEO datasets

On using GEO database (, the NSCLC gene chip map was available to obtain. The database was searched using the following keywords: (Lung) AND (Neoplasm OR Neoplasia OR Tumor OR Cancer OR Carcinoma OR Malignant OR Malignancy) AND (microRNA OR miRNA OR noncodingRNA OR ncRNA OR small RNA). Three microarray datasets related to the expression of miR-126 in NSCLC tissue samples and adjacent noncancerous lung tissue (ANLT) samples were obtained: GSE101929, GSE18842, and GSE19804.

Literature search for studies on miR-126 in NSCLC

The PubMed, China National Knowledge Infrastructure (CNKI) database, Embase, Web of Science databases were searched from inception to 1/4/2020, with the following keywords: (microRNA OR miRNA OR noncoding RNA OR ncRNA OR small RNA) and (126 OR 126-5P) AND (Lung) and (Neoplasm OR Neoplasia OR Tumor OR Cancer OR Carcinoma OR Malignancy OR Malignant).

Studies on the expression of miR-126 in NSCLC were included. The exclusion criteria were: case reports, reviews, meta-analyses, nonclinical studies, studies with no control group, and conference summaries.

Gene Ontology enrichment and target gene prediction

There were 32, 46, and 60 NSCLC samples, and 34, 45, and 60 ANLT samples contained in the GSE101929, GSE18842, and GSE19804 datasets, respectively. GPL570 platform: Affymetrix Human Genome U133 plus 2.0 (Affymetrix; Thermo Fisher Science, Inc., Waltham, MA, USA) was adopted to analyze all data.

Differentially expressed genes (DEGs) between the NSCLC and ANLT samples were identified using Limma software package (version 3.6.3) in R/BioManager. By default, the false discovery rate (FDR) method introduced by Benjamini and Hochberg was employed to adjust P values, thus correcting false positive results. The cutoff criteria were: |log2(FC)| >1 and P<0.05. The platform annotation file, which was downloaded from the database, served as the basis for converting the probe data in the matrix file into gene symbols.

The target genes of hsa-miR-126-5p were predicted using TargetScan ( Then, the overlapping miR-126 target genes and DEGs in NSCLC were subjected to Gene Ontology (GO) analysis and were visualized using Binto plugin for Cytoscape (version 3.7.2). In addition, the Database for Annotation, Visualization and Integrated Discovery (DAVID) was employed to perform Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. FDR ≤0.05 was set as the cutoff criterion. The construction of a protein-protein interaction (PPI) network was carried out with STRING 11.0 (, and the interactions between genes in the network were visualized using the cytoHubba plugin for Cytoscape (version 3.7.2). The cutoff criterion was a confidence score of C ≥0.7. Finally, molecular complex detection (MCODE) was conducted, and the PPI network modules with degree cutoff =2, node score cutoff =0.2, k-core =2, and maximum depth =100 were selected.

Survival analysis

The survival rates of 12 types of cancer, including gastric cancer (n=1,440), ovarian cancer (n=2,190), lung cancer (n=3,452), and breast cancer (n=6,234), were assessed using Kaplan-Meier plotter ( The median expression levels of specific genes were determined, and then, based on the median expression, NSCLC patients were grouped into high-expression and low-expression groups. The Kaplan-Meier method was used to analyze the NSCLC patients’ survival. In the survival analysis of smokers and non-smokers, specific genes showed statistical significance. Hazard ratio (HR) was used as the effect index of survival risk. The GSE102287 dataset was used to verify whether miR-126 has a correlation with DEGs in NSCLC. This analysis included 62 samples.

Statistical analysis

Data were expressed as mean ± standard deviation (SD). T-test was adopted for comparisons between two groups, The correlation between the expression level of miR-126 and NSCLC was also analyzed by standardized mean difference (SMD) analysis using Stata 15.0 statistical software. The Mantel-Haenszel formula (fixed-effects model) or the Der Simonia-Laird formula (random-effects model) was used to combine and analyze different GEO datasets. With P≤0.05 or I2≥50% representing a significant Q statistic, a random-effects model was adopted; otherwise, a fixed-effects model was used. Spearman’s rank correlation was used to analyze the correlation between the expression of DEGs and the levels of miR-126. P<0.05 was considered statistically significant.


miR-126 expression in NSCLC based on GEO

Based on four GEO datasets (GSE102286, GSE29248, GSE63805, and GSE27705), the expression of miR-126 in NSCLC tissue and ANLT was evaluated (Figure 1). Compared with that in ANLT samples, miR-126 expression was significantly up-regulated in NSCLC tissues in the GSE102286, GSE29248, and GSE27705 datasets (P<0.01), but the difference was not significant in GSE63805. Table 1 and Figure 2A,B,C,D show the characteristics of the GEO datasets. In accordance with all the included GEO datasets, a statistically significant difference was identified in miR-126 expression between NSCLC and normal tissues (SMD =−1.69, 95% CI: −2.97 to −0.41, P<0.01). A forest map is shown in Figure 3.

Figure 1 Flow-chart of the research and screening processes for the Gene Expression Omnibus datasets.
Table 1
Table 1 Characteristics of the Gene Expression Omnibus (GEO) datasets
Full table
Figure 2 Expression of miR-126 in NSCLC and normal lung tissues in the GEO datasets. (A) miR-126 expression and GSE27705; (B) miR-126 expression and GSE 29248; (C) miR-126 expression and GSE63805; (D) miR-126 and GSE102268. **, P<0.01; ***, P<0.001. NSCLC, non-small cell lung cancer; GEO, Gene Expression Omnibus; Normal, normal lung tissue; miR-126, hsa-miR-126-5p.
Figure 3 Forest plot of differential expression of miR-126-5p in the GEO datasets. GEO, Gene Expression Omnibus.

Expression profiles of miR-126 in NSCLC and ANLT in the literature

A literature review of studies on the expression of miR-126 in NSCLC was performed. As shown in Figure 4, six studies from the literature that met the selection criteria were selected (14-19). As shown in Table 2, miR-126 expression was significantly decreased in NSCLC tissues in comparison with normal tissues.

Figure 4 Screening of literature on the expression of miR-126-5p in NSCLC. NSCLC, non-small cell lung cancer.
Table 2
Table 2 Studies included from the literature
Full table

miR-126 target prediction and bioinformatics analysis, data preprocessing and screening of DEGs

In the GSE18842, GSE19804, and GSE101929 datasets, 1829, 804, and 1921 DEGs were identified, respectively; 595 common DEGs were obtained from these three datasets using Venny 2.1.0 ( (Figures 5,6). Then, based on TargetScan, 5591 TG_hsa-miR-126-5p were reported, 187 of which overlapped with 595 common DEGs. As could be seen from the GSE101929 data, among the genes associated with hsa-miR-126-5pm in NSCLC tissues, 46 were up-regulated and 141 were down-regulated (Figure 6). Subsequently, the top 10 up-regulated and down-regulated genes were obtained and are shown in Table 3.

Figure 5 Volcano plot of genome-wide mRNA detected from three NSCLC-related datasets from GEO. Red plots: aberrantly expressed mRNAs with P<0.05 and |log2(FC)| >1; red plots above the line: up-regulated genes; red plots below the line: down-regulated genes. Black plots: normally expressed mRNAs. The x-axis represents the adj.P of −log10. P value of each mRNA represents the associated strength. NSCLC, non-small cell lung cancer; GEO, Gene Expression Omnibus; adj.P.Value, adjusted P value; FC, fold change.
Figure 6 Venn diagram of differentially expressed genes related to hsa-miR-126-5p in TG_miR-126-5p and other three GEO datasets; the overlapping region represents the recognized DEGs. DEGs, differentially expressed genes; TG_miR-126-5p, target genes of hsa-miRNA-126-5p.
Table 3
Table 3 Top 10 differentially expressed genes related to hsa-miR-126-5p in NSCLC based on data from Gene Expression Omnibus (GSE101929)
Full table

Functional analysis of miR-126-related DEGs in NSCLC

GO enrichment analysis was performed using Bingo plugin in Cytoscape, and KEGG enrichment analysis was carried out using DAVID. The results of GO enrichment analysis are shown in Figure 7 and Table 4. It was found that many target genes participate in biological processes, mainly including biological regulation, signal receptor binding, cell membrane binding, stimulus response, and glycosaminoglycan binding (Figure 7, Table 4). In addition, KEGG pathway enrichment analysis (Table 4) revealed enrichment in the protein digestion and absorption interaction pathway.

Figure 7 Results of GO enrichment analysis of miR-126 target genes in NSCLC. The yellow circle represents functional enrichment; a larger circle and a darker color show that more genes are enriched in this pathway. The connecting lines represent the associations between genes. NSCLC, non-small cell lung cancer.
Table 4
Table 4 GO and KEGG enrichment analysis of differentially expressed genes related to hsa-miR-126-5p in NSCLC
Full table

PPI network construction and module selection

A PPI network of miR-126-related DEGs was constructed, with 187 nodes and 281 edges (Figure 8). As shown in Figure 9A, with the top 10 hub genes ranked using degree as the criterion, a close association among hub genes was identified. Following that, MCODE was adopted to obtain an important module (Figure 9B) from the above PPI network, with 12 nodes and 64 edges.

Figure 8 Protein-protein interaction network of hsa-miR-126-5p-related differentially expressed genes. The lines represent interaction between nodes, that is, interaction between proteins. Colored nodes: query proteins and first shell of interactors; white nodes: second shell of interactors; empty nodes: proteins of unknown 3D structure; filled nodes: some 3D structures known or predicted. DEGs, differentially expressed genes.
Figure 9 Protein-protein interaction network. (A) Protein-protein interaction network of hub genes of hsa-miR-126-5p-related DEGs; (B) a significant module selected from the protein-protein interaction network of hsa-miR-126-5p-related DEGs. Red and yellow represent the top 10 hub genes. The darker the color, the stronger the association with other genes in the PPI network. The lines represent interaction relationship between nodes. DEGs, differentially expressed genes.

Survival analysis

CCNB1, KIAA0101, BUB1B, TPX2, NUF2, NCAPG, MELK, KIF15, HMMR, and ANLN were the top 10 hub genes in the PPI network. Their prognostic values were assessed using Kaplan-Meier plotter. Analysis of the overall survival of NSCLC patients was performed based on high and low expression of each hub gene. The results of overall survival analysis showed that all 10 genes were related to the prognosis of NSCLC. However, the results were inconsistent when NSCLC patients were divided into smokers and non-smokers. Only three genes showed statistical differences between the smokers and non-smokers, namely NCAPG (HR =1.59, 95% CI: 1.40–1.80, P<0.01), MELK (HR =1.6, 95% CI: 1.41–1.82, P<0.01), and KIAA0101 (HR =1.56, 95% CI: 1.37–1.77, P<0.01), indicating the association of these three genes with a decreased overall survival rate in NSCLC patients (Figure 10). As can be seen in Table 5, the data obtained from the PPI network analysis revealed a negative correlation between miR-126 and the top 10 hub genes, especially ANLN, HMMR, TPX2, and HMMR; these genes might play a role in NSCLC by interacting with miR-126.

Figure 10 Expression of NCAPG, MELK, KIAA0101 and NSCLC prognosis. According to the median expression level, NSCLC patients are grouped according to low expression and high expression. NSCLC, non-small cell lung cancer.
Table 5
Table 5 Correlation between hsa-miR-126 and target genes in NSCLC patients (n=62)
Full table


Based on the datasets from GEO, data from the literature review, and comparison of miRNA expression profiles in NSCLC and normal tissues, the current study revealed a correlation of abnormal miR-126 expression and NSCLC. Moreover, GO, KEGG, PPI network, and Kaplan-Meier survival analyses were employed to identify and analyze the novel markers and potential targets of miR-126, which were involved in the key biological processes in NSCLC

To date, few studies have investigated miR-126 characteristics in NSCLC; however, down-regulation of miR-126 in NSCLC has been confirmed in various clinical studies. For instance, as reported by Wang et al. (20) in 2015, early-stage NSCLC patients had lower miR-126 expression in the blood, which was consistent with findings of Zhu et al. (21) and Shang et al. (22). Therefore, miR-126 is considered to be a diagnostic marker of early-stage NSCLC.

In NSCLC patients, the level of miR-126 is not only decreased in body fluids, but it is also lower in tumor tissues than in the adjacent normal tissues (14,15); a significant association has been identified between decreased miR-126 expression and NSCLC prognosis (16,17). A significant decrease of miR-126 expression was found in NSCLC tissues in three out of the four GSE datasets used in this study; a statistically significant combined SMD was obtained from the meta-analysis. Therefore, it is of great significance to further study the mechanism of miR-126, so as to identify its target genes and potential therapeutic targets for NSCLC.

MiR-126, as a crucial mRNA, participates in NSCLC regulation. A meta-analysis by Zheng et al. (23), for instance, pointed out a positive relationship of increased NSCLC overall survival and high expression of miR-126. MiR-126-3p can hamper the growth, migration, and invasion of NSCLC cells by targeting the CCR1 gene (24). The enzyme activity of mitochondrial respiration and Malate Dehydrogenase 1 (MDH1) in NSCLC cells can be inhibited by miR-126-5p, thereby resulting in cell death (25). NSCLC cell growth is promoted by up-regulated long-chain non-coding RNA (lncRNA) MINCR through a negative regulatory relationship with miR-126/SLC7A5 (26). Guo et al. (27) also found a regulatory effect of lncRNA PRNCR1 on NSCLC cell invasion, migration, apoptosis, and proliferation via the PRNCR1/miR-126-5p/MTDH axis. In view of the current situation, further investigation of the molecular mechanisms and clinical value of abnormal miR-126 expression in NSCLC is required. The high correlation of 10 hub genes was revealed in PPI network analysis, and the association of these genes and NSCLC prognosis was obtained from the survival analysis. However, another analysis of NSCLC prognosis was carried out in smokers and non-smokers due to the significant effect of smoking on lung cancer. After stratified analysis, some genes were no longer significant, and only the expression levels of three genes (NCAPG, MELK, and KIAA0101) were significantly related to the prognosis of NSCLC, regardless of smoking status; high expression of these three genes was associated with a poor NSCLC prognosis. This result also confirms the negative regulatory effect of miR-126.

NCAPG (non-SMC condensin I complex, subunit G), a subunit of the agglutinin complex, participates in the condensation and stabilization of chromosomes in the processes of mitosis and meiosis (28). In renal cell carcinoma, NCAPG can be used as a candidate biomarker (29). MELK (maternal embryo leucine zipper kinase), a member of the CAMK serine/threonine protein kinase superfamily, is most active in the process of mitosis. Zang et al. reported that a high expression of MELK leads to poor prognosis in NSCLC (30); our study has reached the same conclusion. KIAA0101 mainly plays a role in the liver, but its relationship with other organs has been studied less. In the study of Kato et al. (31), overexpression of KIAA0101 was shown to be a predictor of poor prognosis in primary lung cancer, which is similar to our results. Overall, these three genes have the possibility to be novel prognostic markers for NSCLC.

The new candidate target genes of miR-126 in our study, such as TPX2, HMMR, and ANLN, were found to be involved in the regulation of key biological processes of NSCLC. TPX2 was reported to have a relationship with poor NSCLC prognosis in the study of Schneider et al. (32). HMMR is identified as a polyhedral molecule, which has a tumor-promoting effect. The product of HMMR, hyaluronic acid-mediated cell migration receptor (RHAMM), also promotes the occurrence and development of tumors. Specifically, RHAMM promotes the migration of tumor cells and has a correlation with tumor pathological stage (33). The expression of A549 anillin (ANLN) gene in human lung adenocarcinoma cells is suppressed by carbon ion irradiation via activation of the P13K/Akt signaling pathway. ANLN has been demonstrated to be inhibited through the P13K/Akt signaling pathway (34). Negative correlations with significant differences were revealed between miR-126 and TPX2, HMMR, and ANLN in NSCLC in our study, suggesting their important biological regulatory role in NSCLC.

In summary, miR-126 has a critical biological role in NSCLC. However, the pathogenesis and the effect of the molecular network regulated by miR-126 in this disease still needs to be determined by further in vitro and in vivo experiments in the future.


Funding: Our work is supported by Natural Science Foundation of Jiangsu Province, Grant/Award No. BK20140601.


Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca A Cancer Journal for Clinicians 2018;68:7-30. [Crossref] [PubMed]
  2. Parascandola M, Xiao L. Tobacco and the lung cancer epidemic in China. Transl Lung Cancer Res 2019;8:S21-30. [Crossref] [PubMed]
  3. Ahn S, Jeong JY, Kim HW, et al. Robotic lobectomy for lung cancer: initial experience of a single institution in Korea. Ann Cardiothorac Surg 2019;8:226-32. [Crossref] [PubMed]
  4. Sacco PC, Maione P, Guida C, et al. The combination of new immunotherapy and radiotherapy: a new potential treatment for locally advanced non-small cell lung cancer. Curr Clin Pharmacol 2017;12:4-10. [Crossref] [PubMed]
  5. Bagley SJ, Talento S, Mitra N, et al. Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous non-small cell lung cancer. J Natl Compr Canc Netw 2019;17:469-77. [Crossref] [PubMed]
  6. Helman E, Nguyen M, Karlovich CA, et al. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clin Lung Cancer 2018;19:518-530.e7. [Crossref] [PubMed]
  7. Ma N, Wei T, Wang B, et al. MicroRNA-142-3p inhibits IFN-gamma production via targeting of RICTOR in Aspergillus fumigatus activated CD4(+) T cells. Ann Transl Med 2019;7:649. [Crossref] [PubMed]
  8. Fan J, Xu W, Nan S, et al. MicroRNA-384-5p Promotes Endothelial Progenitor Cell Proliferation and Angiogenesis in Cerebral Ischemic Stroke through the Delta-Likeligand 4-Mediated Notch Signaling Pathway. Cerebrovasc Dis 2020;49:39-54. [Crossref] [PubMed]
  9. Jacques C, Tesfaye R, Lavaud M, et al. Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas. Cells 2020;9:810. [Crossref] [PubMed]
  10. Wei L, Chen Z, Cheng N, et al. MicroRNA-126 Inhibit Viability of Colorectal Cancer Cell by Repressing mTOR Induced Apoptosis and Autophagy. Onco Targets Ther 2020;13:2459-68. [Crossref] [PubMed]
  11. Tomasetti M, Gaetani S, Monaco F, et al. Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy. Front Oncol 2019;9:1293. [Crossref] [PubMed]
  12. Kim JY, Lee DH, Kim JK, et al. ETV2/ER71 regulates the generation of FLK1(+) cells from mouse embryonic stem cells through miR-126-MAPK signaling. Stem Cell Res Ther 2019;10:328. [Crossref] [PubMed]
  13. Zhang Z, Wang J, Cheng J, et al. Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett 2018;15:8412-6. [Crossref] [PubMed]
  14. Begum S, Hayashi M, Ogawa T, et al. An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. Sci Rep 2015;5:13236. [Crossref] [PubMed]
  15. Świtlik W, Karbownik MS, Suwalski M, et al. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Cancer Biomark 2018;21:479-88. [Crossref] [PubMed]
  16. Yang J, Lan H, Huang X, et al. MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer Patients. PLos One 2012;7:e42978. [Crossref] [PubMed]
  17. Kim MK, Jung SB, Kim JS, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch 2014;465:463-71. [Crossref] [PubMed]
  18. Li XG, Wan GS, Liang YX, et al. Effect of miR-126 on cell cycle regulation and prognosis of lung cancer patients. Journal of Practical Oncology 2014;29:440-5.
  19. Chen SW, Wang TB, Tian YH, et al. Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer. Int J Clin Exp Pathol 2015;8:14983-8. [PubMed]
  20. Wang P, Yang D, Zhang H, et al. Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers. Clin Lung Cancer 2015;16:313-9.e1. [Crossref] [PubMed]
  21. Zhu W, Zhou K, Zha Y, et al. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer. PLos One 2016;11:e0153046. [Crossref] [PubMed]
  22. Shang AQ, Xie YN, Wang J, et al. Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study. Neoplasma 2017;64:453-9. [Crossref] [PubMed]
  23. Zheng W, Zhou Y, Lu J, et al. The prognostic value of miR-126 expression in non-small-cell lung cancer: a meta-analysis. Cancer Cell Int 2017;17:71. [Crossref] [PubMed]
  24. Liu R, Zhang YS, Zhang S, et al. MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1. Eur Rev Med Pharmacol Sci 2019;23:679-89. [PubMed]
  25. Lima Queiroz A, Zhang B, Comstock DE, et al. miR-126-5p targets Malate Dehydrogenase 1 in non-small cell lung carcinomas. Biochem Biophys Res Commun 2018;499:314-20. [Crossref] [PubMed]
  26. Wang J, Ding M, Zhu H, et al. Up-regulation of long noncoding RNA MINCR promotes non-small cell of lung cancer growth by negatively regulating miR-126/SLC7A5 axis. Biochem Biophys Res Commun 2019;508:780-4. [Crossref] [PubMed]
  27. Guo R, Hu T, Liu Y, et al. Long non-coding RNA PRNCR1 modulates non-small cell lung cancer cells proliferation, apoptosis, migration, invasion and EMT through PRNCR1/miR-126-5p/MTDH axis. Biosci Rep 2020;40:BSR20193153. [Crossref] [PubMed]
  28. Sutani T, Sakata T, Nakato R, et al. Condensin targets and reduces unwound DNA structures associated with transcription in mitotic chromosome condensation. Nat Commun 2015;6:7815. [Crossref] [PubMed]
  29. Kim DS, Choi YP, Kang S, et al. Panel of candidate biomarkers for renal cell carcinoma. J Proteome Res 2010;9:3710-9. [Crossref] [PubMed]
  30. Zang X, Qian C, Ruan Y, et al. Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients. Biomark Med 2019;13:1349-61. [Crossref] [PubMed]
  31. Kato T, Daigo Y, Aragaki M, et al. Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer 2012;75:110-8. [Crossref] [PubMed]
  32. Schneider MA, Christopoulos P, Muley T, et al. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol 2017;50:365-72. [Crossref] [PubMed]
  33. Isakova JT, Vinnikov D, Kipen VN, et al. Gene-to-gene interactions and the association of TP53, XRCC1, TNFalpha, HMMR, MDM2 and PALB2 with breast cancer in Kyrgyz females. Breast Cancer 2020;27:938-46. [Crossref] [PubMed]
  34. Ogata T, Teshima T, Inaoka M, et al. Carbon ion irradiation suppresses metastatic potential of human non-small cell lung cancer A549 cells through the phosphatidylinositol-3-kinase/Akt signaling pathway. J Radiat Res 2011;52:374-9. [Crossref] [PubMed]

(English Language Editor: J. Reynolds)

Cite this article as: Jiao Z, Yu A, He X, Xuan Y, Zhang H, Wang G, Shi M, Wang T. Bioinformatics analysis to determine the prognostic value and prospective pathway signaling of miR-126 in non-small cell lung cancer. Ann Transl Med 2020;8(24):1639. doi: 10.21037/atm-20-7520